185 related articles for article (PubMed ID: 29482985)
1. Loss of p27
Kim GJ; Kim DH; Min KW; Kim YH; Oh YH
Pathol Res Pract; 2018 Apr; 214(4):565-571. PubMed ID: 29482985
[TBL] [Abstract][Full Text] [Related]
2. Expression of p21(Wafl/Cip1), p57(Kip2) and HER2/neu in patients with gallbladder cancer.
Puhalla H; Wrba F; Kandioler D; Lehnert M; Huynh A; Gruenberger T; Tamandl D; Filipits M
Anticancer Res; 2007; 27(3B):1679-84. PubMed ID: 17595796
[TBL] [Abstract][Full Text] [Related]
3. Significance of p57(Kip2) down-regulation in oncogenesis of bladder carcinoma: an immunohistochemical study.
Bozdoğan O; Atasoy P; Batislam E; Başar MM; Başar H
Tumori; 2008; 94(4):556-62. PubMed ID: 18822693
[TBL] [Abstract][Full Text] [Related]
4. Different expression patterns of p27 and p57 proteins in benign and malignant melanocytic neoplasms and in cultured human melanocytes.
Curry JL; Richards HW; Huttenbach YT; Medrano EE; Reed JA
J Cutan Pathol; 2009 Feb; 36(2):197-205. PubMed ID: 18647205
[TBL] [Abstract][Full Text] [Related]
5. Cyclic changes in the expression of p57(kip2) in human endometrium and its regulation by steroid hormones in endometrial stromal cells in vitro.
Kim ST; Lee SK; Gye MC
Reprod Sci; 2012 Jan; 19(1):92-101. PubMed ID: 22064387
[TBL] [Abstract][Full Text] [Related]
6. Distinct developmental roles of cell cycle inhibitors p57Kip2 and p27Kip1 distinguish pituitary progenitor cell cycle exit from cell cycle reentry of differentiated cells.
Bilodeau S; Roussel-Gervais A; Drouin J
Mol Cell Biol; 2009 Apr; 29(7):1895-908. PubMed ID: 19139274
[TBL] [Abstract][Full Text] [Related]
7. Expression of p57(KIP2) in hepatocellular carcinoma: relationship between tumor differentiation and patient survival.
Nakai S; Masaki T; Shiratori Y; Ohgi T; Morishita A; Kurokohchi K; Watanabe S; Kuriyama S
Int J Oncol; 2002 Apr; 20(4):769-75. PubMed ID: 11894123
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in nonsmall cell lung cancer.
Pateras IS; Apostolopoulou K; Koutsami M; Evangelou K; Tsantoulis P; Liloglou T; Nikolaidis G; Sigala F; Kittas C; Field JK; Kotsinas A; Gorgoulis VG
Int J Cancer; 2006 Dec; 119(11):2546-56. PubMed ID: 16988944
[TBL] [Abstract][Full Text] [Related]
9. Ubiquitylation and proteasomal degradation of the p21(Cip1), p27(Kip1) and p57(Kip2) CDK inhibitors.
Lu Z; Hunter T
Cell Cycle; 2010 Jun; 9(12):2342-52. PubMed ID: 20519948
[TBL] [Abstract][Full Text] [Related]
10. ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab.
Kurozumi S; Inoue K; Takei H; Matsumoto H; Kurosumi M; Horiguchi J; Takeyoshi I; Oyama T
BMC Cancer; 2015 Sep; 15():622. PubMed ID: 26345461
[TBL] [Abstract][Full Text] [Related]
11. The cyclin kinase inhibitor p57kip2 regulates TGF-beta-induced compensatory tubular hypertrophy: effect of the immunomodulator AS101.
Sinuani I; Weissgarten J; Beberashvili I; Rapoport MJ; Sandbank J; Feldman L; Albeck M; Averbukh Z; Sredni B
Nephrol Dial Transplant; 2009 Aug; 24(8):2328-38. PubMed ID: 19321762
[TBL] [Abstract][Full Text] [Related]
12. The cyclin-dependent kinase inhibitor p57Kip2 regulates cell cycle exit, differentiation, and migration of embryonic cerebral cortical precursors.
Tury A; Mairet-Coello G; DiCicco-Bloom E
Cereb Cortex; 2011 Aug; 21(8):1840-56. PubMed ID: 21245411
[TBL] [Abstract][Full Text] [Related]
13. Disappearance of p27(KIP1) and increase in proliferation of the lens cells after extraction of most of the fiber cells of the lens.
Kase S; Yoshida K; Ikeda H; Harada T; Harada C; Imaki J; Ohgami K; Shiratori K; Nakayama KI; Nakayama K; Ohno S
Curr Eye Res; 2005 Jun; 30(6):437-42. PubMed ID: 16020276
[TBL] [Abstract][Full Text] [Related]
14. Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.
Esteva FJ; Sahin AA; Rassidakis GZ; Yuan LX; Smith TL; Yang Y; Gilcrease MZ; Cristofanilli M; Nahta R; Pusztai L; Claret FX
Clin Cancer Res; 2003 Nov; 9(15):5652-9. PubMed ID: 14654548
[TBL] [Abstract][Full Text] [Related]
15. p57(Kip2) and p27(Kip1) cooperate to maintain hematopoietic stem cell quiescence through interactions with Hsc70.
Zou P; Yoshihara H; Hosokawa K; Tai I; Shinmyozu K; Tsukahara F; Maru Y; Nakayama K; Nakayama KI; Suda T
Cell Stem Cell; 2011 Sep; 9(3):247-61. PubMed ID: 21885020
[TBL] [Abstract][Full Text] [Related]
16. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
[TBL] [Abstract][Full Text] [Related]
17. Regulation of p27
Russo GL; Stampone E; Cervellera C; Borriello A
Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32933137
[TBL] [Abstract][Full Text] [Related]
18. p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy.
Porter PL; Barlow WE; Yeh IT; Lin MG; Yuan XP; Donato E; Sledge GW; Shapiro CL; Ingle JN; Haskell CM; Albain KS; Roberts JM; Livingston RB; Hayes DF
J Natl Cancer Inst; 2006 Dec; 98(23):1723-31. PubMed ID: 17148774
[TBL] [Abstract][Full Text] [Related]
19. P21-activated kinase 4 regulates the cyclin-dependent kinase inhibitor p57(kip2) in human breast cancer.
Li Y; Wang D; Zhang H; Wang C; Dai W; Cheng Z; Wang G; Li F
Anat Rec (Hoboken); 2013 Oct; 296(10):1561-7. PubMed ID: 23873832
[TBL] [Abstract][Full Text] [Related]
20. Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy.
Kim JW; Kim JH; Im SA; Lee KH; Kim JS; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1023-9. PubMed ID: 24036907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
